Dartmouth-Hitchcock Medical Center
Latest From Dartmouth-Hitchcock Medical Center
Masimo has gained FDA clearance for its Root Patient Monitoring Platform, a noninvasive, continuous monitoring platform with interoperability and technologies that have demonstrated improved patient safety and cost of care.
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
The US endovascular abdominal aortic aneurysm repair (EVAR) market is one of the most dynamic device segments in the interventional arena, with growth and innovation driven in large part by an accelerating effort to expand EVAR to a wider patient pool. This movement toward more challenging cases does have a downside in terms of potential complications and uncertain long-term durability as physicians push the envelope of existing technology. However, innovation in this field is continuing at a fairly steady pace, and several important new technologies that could improve the safety and durability of EVAR in more complex anatomy could be introduced in the near future. If these devices live up to their early promise, they are likely to ignite even stronger growth in a market already valued at over $1 billion annually worldwide.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.